255 related articles for article (PubMed ID: 34218714)
1. Recurrent Priapism From Cabergoline and Bromocriptine in a Hypogonadal Man With Prolactinoma.
Menon LP; Rahman W
J Investig Med High Impact Case Rep; 2021; 9():23247096211029750. PubMed ID: 34218714
[TBL] [Abstract][Full Text] [Related]
2. The use of high-dose daily cabergoline in an adolescent patient with macroprolactinoma.
Howell DL; Wasilewski K; Mazewski CM; Hudgins RJ; Meacham LR
J Pediatr Hematol Oncol; 2005 Jun; 27(6):326-9. PubMed ID: 15956887
[TBL] [Abstract][Full Text] [Related]
3. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment.
Elenkova A; Shabani R; Kalinov K; Zacharieva S
Eur J Endocrinol; 2012 Jul; 167(1):17-25. PubMed ID: 22511808
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
Sabuncu T; Arikan E; Tasan E; Hatemi H
Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
[TBL] [Abstract][Full Text] [Related]
5. Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas.
Iyer P; Molitch ME
Endocr Pract; 2011; 17(3):e55-8. PubMed ID: 21324816
[TBL] [Abstract][Full Text] [Related]
6. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine.
Delgrange E; Maiter D; Donckier J
Eur J Endocrinol; 1996 Apr; 134(4):454-6. PubMed ID: 8640297
[TBL] [Abstract][Full Text] [Related]
7. Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists.
De Sousa SM; Chapman IM; Falhammar H; Torpy DJ
Endocrine; 2017 Feb; 55(2):618-624. PubMed ID: 27601019
[TBL] [Abstract][Full Text] [Related]
8. CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas.
Leong KS; Foy PM; Swift AC; Atkin SL; Hadden DR; MacFarlane IA
Clin Endocrinol (Oxf); 2000 Jan; 52(1):43-9. PubMed ID: 10651752
[TBL] [Abstract][Full Text] [Related]
9. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
[TBL] [Abstract][Full Text] [Related]
10. Dopamine receptor agonists for treating prolactinomas.
Colao A; di Sarno A; Pivonello R; di Somma C; Lombardi G
Expert Opin Investig Drugs; 2002 Jun; 11(6):787-800. PubMed ID: 12036422
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness Analysis of Microscopic and Endoscopic Transsphenoidal Surgery Versus Medical Therapy in the Management of Microprolactinoma in the United States.
Jethwa PR; Patel TD; Hajart AF; Eloy JA; Couldwell WT; Liu JK
World Neurosurg; 2016 Mar; 87():65-76. PubMed ID: 26548828
[TBL] [Abstract][Full Text] [Related]
13. Brain and optic chiasmal herniation following cabergoline treatment for a giant prolactinoma: wait or intervene?
Papanastasiou L; Fountoulakis S; Pappa T; Liberopoulos K; Malliopoulos D; Markou A; Piaditis G
Hormones (Athens); 2014; 13(2):290-5. PubMed ID: 24776630
[TBL] [Abstract][Full Text] [Related]
14. Pituitary apoplexy associated with cabergoline therapy.
Chng E; Dalan R
J Clin Neurosci; 2013 Dec; 20(12):1637-43. PubMed ID: 24113159
[TBL] [Abstract][Full Text] [Related]
15. Hyperprolactinemia: pathophysiology and management.
Verhelst J; Abs R
Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552
[TBL] [Abstract][Full Text] [Related]
16. Combined cabergoline and recombinant human growth hormone treatment of an adolescent with a macroprolactinoma causing GH deficiency.
Cesario F; Borretta G; Meineri I; Muratori M; Pizzocaro A; Beck-Peccoz P
J Pediatr Endocrinol Metab; 1997; 10(2):231-6. PubMed ID: 9364359
[TBL] [Abstract][Full Text] [Related]
17. Cabergoline in the long-term therapy of hyperprolactinemic disorders.
Ferrari C; Paracchi A; Mattei AM; de Vincentiis S; D'Alberton A; Crosignani P
Acta Endocrinol (Copenh); 1992 Jun; 126(6):489-94. PubMed ID: 1642081
[TBL] [Abstract][Full Text] [Related]
18. Optimal effective doses of cabergoline and bromocriptine and valvular leasions in men with prolactinomas.
Yarman S; Kurtulmus N; Bilge A
Neuro Endocrinol Lett; 2012; 33(3):340-6. PubMed ID: 22635095
[TBL] [Abstract][Full Text] [Related]
19. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
[TBL] [Abstract][Full Text] [Related]
20. Macroprolactinoma with secondary resistance to dopamine agonists: a case report and review of the literature.
Tng EL; Teo AE; Aung AT
J Med Case Rep; 2023 Mar; 17(1):96. PubMed ID: 36927797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]